SAB Biotherapeutics, Inc. (SABS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the SAB BIOS conference call to discuss first quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking statements from the morning's quarterly earnings press release. Company management may provide projections during the call and actual results could differ materially due to several factors such including those outlined in the company's latest filings with the SEC. Currently, all participants are in a listen-only mode. Following management's remarks, we will open the call for questions. This call is being webcast live and can be accessed on the investor section of SABBIO's website at ir.sab.bio.com. where a replay will be available. I'll now turn the call over to Samuel Reich, Chief Executive Officer of SAB Bio. Thank you, Operator. Good morning, and thank you to everyone joining us for our first earnings call. We're excited to have you with us to share the progress our team has made in the first quarter, progress that sets a strong foundation for the rest of 2026. For those of you who may be new to our story, let me take a moment to introduce SAB Bio, our mission, and our focus. SAB Bio is a clinical stage biopharmaceutical company focused on developing fully human anti-thymocyte immunoglobulin for type 1 diabetes and other autoimmune diseases. Our mission is to dramatically redefine what it means to be diagnosed with type 1 diabetes by developing a medicine to change the course of disease, not just treat the symptoms. Our lead product candidate, SAB142, is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes. We produce SAB142 using our proprietary TC Bovine platform, which allows us to generate ful...